



Stabilis



Diphenhydramine hydrochloride



Noms commerciaux

Benadryl	
Benison	Turquie
Dibondrin	Autriche



Stabilité des solutions

PVC		0,2 mg/ml	2-8°C		14			4185
PVC		0,25 & 0,5 & 1 mg/ml	22°C		91			1277
PVC		0,25 & 0,5 & 1 mg/ml	4°C		91			1277
PVC		1 mg/ml	2-8°C		14			4185
PP		0,25 & 2,5 & 5 mg/ml	22°C		28			1277
PP		0,25 & 2,5 & 5 mg/ml	4°C		28			1277
























































Stabilité en mélange

		0,5 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4	
PP		4 mg/ml	25°C		Dexamethasone sodium phosphate : 0.27 mg/ml Lorazepam : 0.16 mg/ml	48	
PP		50 mg/ml	25°C		Paracetamol : 10 mg/ml	4	
		2 mg/ml	25°C		Metoclopramide hydrochloride : 1,6 mg/ml Dexamethasone sodium phosphate : 0,16 mg/ml	48	



Compatibilités

				
		Diphenhydramine hydrochloride : 50 mg/ml Aciclovir sodium : 5 mg/ml		2335
		Diphenhydramine hydrochloride : 1 mg/ml Aciclovir sodium : 5 mg/ml		336
		Diphenhydramine hydrochloride : 50 mg/ml Aldesleukin : 0.0338 MUI/ml		36
		Diphenhydramine hydrochloride : 2 mg/ml Allopurinol sodium : 3 mg/ml		307
		Diphenhydramine hydrochloride : 2 mg/ml Amifostine : 10 mg/ml		3
		Diphenhydramine hydrochloride : 50 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Diphenhydramine hydrochloride : 2 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Diphenhydramine hydrochloride : 2 mg/ml Amsacrine : 1 mg/ml		253
		Diphenhydramine hydrochloride : 50 mg/ml Argatroban : 1 mg/ml		1964
		Diphenhydramine hydrochloride : 50 mg/ml Azithromycine : 2 mg/ml		1800
		Diphenhydramine hydrochloride : 2 mg/ml Aztreonam : 40 mg/ml		99
		Diphenhydramine hydrochloride : 2 mg/ml Bivalirudin : 5 mg/ml		1713
		Diphenhydramine hydrochloride : 50 mg/ml Caffeine : 10 mg/ml		3964
		Diphenhydramine hydrochloride : 50 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Diphenhydramine hydrochloride : 50 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Diphenhydramine hydrochloride : 50 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Diphenhydramine hydrochloride : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Diphenhydramine hydrochloride : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Diphenhydramine hydrochloride : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Diphenhydramine hydrochloride Ceftobiprole medocaril sodium		4650
		Diphenhydramine hydrochloride : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Diphenhydramine hydrochloride : 50 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Diphenhydramine hydrochloride : 50 mg/ml Chlorpromazine hydrochloride : 25 mg/ml		188
		Diphenhydramine hydrochloride : 50 mg/ml Cimetidine hydrochloride : 150 mg/ml		1438

		Diphenhydramine hydrochloride : 50 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Diphenhydramine hydrochloride : 2 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Diphenhydramine hydrochloride : 2 mg/ml Cladribine : 0.5 mg/ml		1496
		Diphenhydramine hydrochloride : 2 mg/ml Cladribine : 0.015 mg/ml		1496
		Diphenhydramine hydrochloride : 50 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Diphenhydramine hydrochloride : < 5 mg/ml Dexamethasone sodium phosphate : 4 >> 10 mg/ml		389
		Diphenhydramine hydrochloride : 40 mg/ml Dexamethasone sodium phosphate : 2 mg/ml		389
		Diphenhydramine hydrochloride : 5 >> 35 mg/ml Dexamethasone sodium phosphate : 2 >> 10 mg/ml		389
		Diphenhydramine hydrochloride : 2 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Diphenhydramine hydrochloride : 50 mg/ml Diatrizoate meglumine : 283 mg/ml		1085
		Diphenhydramine hydrochloride : 2 mg/ml Docetaxel : 0.9 mg/ml		1754
		Diphenhydramine hydrochloride : 2 mg/ml Doripenem : 5 mg/ml		2262
		Diphenhydramine hydrochloride : 2 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Diphenhydramine hydrochloride : 2 mg/ml Fentanyl citrate : 25 µg/ml		1974
		Diphenhydramine hydrochloride : 2 & 50 mg/ml		301
		Diphenhydramine hydrochloride : 2 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Diphenhydramine hydrochloride : 2 mg/ml Famotidine : 2 mg/ml		215
		Diphenhydramine hydrochloride : 2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Diphenhydramine hydrochloride : 2 mg/ml Filgrastim : 30 µg/ml		244
		Diphenhydramine hydrochloride : 50 mg/ml Fluconazole : 2 mg/ml		496
		Diphenhydramine hydrochloride : 2 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Diphenhydramine hydrochloride : 50 mg/ml Foscarnet sodium : 24 mg/ml		73
		Diphenhydramine hydrochloride : 50 mg/ml Fosfomicin : 30 mg/ml		4055
		Diphenhydramine hydrochloride : 50 mg/ml Gallium nitrate : 1 mg/ml		91
		Diphenhydramine hydrochloride : 50 mg/ml Heparin sodium : 1 UI/ml		1228
		Diphenhydramine hydrochloride : 2 & 50 mg/ml		1415
		Diphenhydramine hydrochloride : 2 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423

		Diphenhydramine hydrochloride Haloperidol lactate		985
		Diphenhydramine hydrochloride : 50 mg/ml	RL	4603
		Diphenhydramine hydrochloride : 1 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Diphenhydramine hydrochloride : 2 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Diphenhydramine hydrochloride : 50 mg/ml Haloperidol lactate : 5 mg/ml		982
		Diphenhydramine hydrochloride : 50 mg/ml Haloperidol lactate : 5 mg/ml		188
		Diphenhydramine hydrochloride : 50 mg/ml Heparin sodium : 1 UI/ml	RL	1228
		Diphenhydramine hydrochloride : 2 mg/ml Hetastarch : 60 mg/ml		1721
		Diphenhydramine hydrochloride : 50 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
		Diphenhydramine hydrochloride : 50 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
		Diphenhydramine hydrochloride : 2 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		1974
		Diphenhydramine hydrochloride : 1 & 50 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Diphenhydramine hydrochloride : 50 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Diphenhydramine hydrochloride : 50 mg/ml Iohexol : 300 mg I/ml		1085
		Diphenhydramine hydrochloride : 50 mg/ml Ioxaglate : 320 mg I/ml		1085
		Diphenhydramine hydrochloride : 50 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Diphenhydramine hydrochloride : 50 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Diphenhydramine hydrochloride : 2 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Diphenhydramine hydrochloride : 2 mg/ml Linezolid : 2 mg/ml		1925
		Diphenhydramine hydrochloride : 2 mg/ml Melphalan : 0.1 mg/ml		169
		Diphenhydramine hydrochloride : 0.08 mg/ml Meropenem : 1 & 20 mg/ml		266
		Diphenhydramine hydrochloride : 50 mg/ml Meropenem : 1 & 50 mg/ml		266
		Diphenhydramine hydrochloride : 2 mg/ml Methadone hydrochloride : 1 mg/ml		1974
		Diphenhydramine hydrochloride : 25 mg/ml Midazolam hydrochloride : 2.5 mg/ml		404
		Diphenhydramine hydrochloride : 2 mg/ml Morphine sulfate : 1 mg/ml		1974
		Diphenhydramine hydrochloride : 50 mg/ml N-acetylcysteine : 200 mg/ml		3766

	Diphenhydramine hydrochloride : 50 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
	Diphenhydramine hydrochloride : 0.4 mg/ml Netilmicin sulfate : 3 mg/ml		1200
	Diphenhydramine hydrochloride : 2 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Diphenhydramine hydrochloride : 2 mg/ml Oxaliplatin : 0,5 mg/ml		1662
	Diphenhydramine hydrochloride : 2 mg/ml Paclitaxel : 1.2 mg/ml		85
			2090
	Diphenhydramine hydrochloride : 50 mg/ml Paracetamol : 10 mg/ml		4742
	Diphenhydramine hydrochloride : 50 mg/ml Paracetamol : 10 mg/ml	∅	3571
	Diphenhydramine hydrochloride : 2 mg/ml Pemetrexed disodium : 20 mg/ml		1953
	Diphenhydramine hydrochloride : 1&50 mg/ml Pethidine hydrochloride : 10 mg/ml		62
	Diphenhydramine hydrochloride : 2 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
	Diphenhydramine hydrochloride : 50 mg/ml Plazomicin sulfate : 24 mg/ml		4145
	Diphenhydramine hydrochloride : 50 mg/ml Potassium chloride : 40 mEq/l	RL	1228
	Diphenhydramine hydrochloride : 50 mg/ml Potassium chloride : 40 mEq/l		1228
	Diphenhydramine hydrochloride : 2 mg/ml Propofol : 10 mg/ml	∅	300
	Diphenhydramine hydrochloride : 50 mg/ml Ranitidine hydrochloride : 25 mg/ml	∅	58
	Diphenhydramine hydrochloride : 2 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
	Diphenhydramine hydrochloride : 50 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
	Diphenhydramine hydrochloride : 1 mg/ml Sargramostim : 10 µg/ml		335
	Diphenhydramine hydrochloride : 50 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Diphenhydramine hydrochloride : 1 mg/ml Tacrolimus : 1000 µg/ml		479
			3827
	Diphenhydramine hydrochloride : 2 mg/ml Teniposide : 0.1 mg/ml		905
			3767
	Diphenhydramine hydrochloride : 2 mg/ml Thiotepa : 1 mg/ml		249
	Diphenhydramine hydrochloride : 2 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
57	Revue	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Revue	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.

99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
188	Revue	Gibler B, Kim MS, Raleigh F. Visual compatibility of neuroleptics with anticholinergics or antihistamines in polyethylene syringes. Am J Hosp Pharm 1994 ; 51: 2709-2710.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.

335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
389	Revue	Walker SE, DeAngelis C, Iazzetta J, Eppel JG. Compatibility of dexamethasone sodium phosphate with hydromorphone hydrochloride or diphenhydramine hydrochloride. Am J Hosp Pharm 1991 ; 48: 2161-2166.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
982	Revue	Ukhun IA. Compatibility of haloperidol and diphenhydramine in a hypodermic syringes. Ann Pharmacotherapy 1995 ; 29: 1168.
985	Revue	Raleigh FR, Gibler BS. Haloperidol and diphenhydramine compatibility. Ann Pharmacotherapy 1996 ; 30: 549.
1085	Revue	Irving HD, Burbridge BE. Incompatibility of contrast agents with intravascular medications. Radiology 1989 ; 173: 91-92.
1200	Revue	Chaudry IA, Bruely KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1277	Revue	Donnelly RF. Chemical stability of diphenhydramine hydrochloride in minibags and polypropylene syringes. Can J Hosp Pharm 1999 ; 52: 150-155.

1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1438	Revue	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1964	Revue	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opioids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.

2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2132	Revue	Anderson Collin R, Halford Zachery, MacKay Mark. Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes. Int J Pharm Compound 2015 ; 19, 4 : 344-347.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2335	Revue	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3779	Revue	Kintzel P.E, Zhao T, Wen B, Sun D. Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection Am J Health-Syst Pharm 2014 ; 71:2061-2065
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98

3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolin/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4185	Revue	Sabins D, Diep T, McCartan P, Patel S, Zhao F Stability and Compatibility of Diphenhydramine Hydrochloride in Intravenous Admixtures : A New Look at an Old Drug. Hosp Pharm 2019 ; 54, 5: 330-334.
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhasan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

	Antihistaminique H1		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	NaCl 0,9% ou glucose 5%		Non précisée
	Jour		A l'abri de la lumière
	Seringue polypropylène		Stabilité en mélange
	Solvant		Molécule
	Verre		Chlorure de sodium 0,9%
	Heure		Polypropylène
	Lumière		Eau pour préparation injectable
	Non précisé		Compatibilités
	Précipitation immédiate		Incompatible
	Compatible		Glucose 5%
	Changement de couleur		Aucun
RL	Ringer lactate		Incompatibilité non précisée
	NaCl 0,9% + bactériostatique		Nutrition parentérale (mélange binaire)
	Turbidité immédiate		Nutrition parentérale (mélange ternaire)
	Précipitation en 2 heures		Solvant spécifique
	Turbidité en 2 heures		Voie d'administration
	Intraveineuse		Intramusculaire
	Bibliographie		Dictionnaire